摘要
目的:分析比较紫杉醇联合替吉奥与奥沙利铂联合替吉奥在胃癌(GC)辅助化疗中的的应用效果。方法:选取2016年10月至2018年10月我院诊治的73例GC晚期患者为主要研究对象,均经手术病理确诊。按照简单随机数字表法分为观察组(n=36,采用奥沙利铂+替吉奥化疗)和对照组(n=37,采用替吉奥+紫杉醇化疗)。观察比较两组的近期疗效及免疫功能指标变化;随访截止至2019年10月31日,记录无疾病进展生存期(PFS)总生存时间(OS),两组术后复发率及发生的不良反应。结果:两组疾病控制率、术后复发率、PFS、OS间差异均无统计学意义(P>0.05);与化疗前比,两组化疗后的Ig A、IgG及IgM指标均较化疗前有明显升高(P<0.05);而与对照组比,观察组化疗后的Ig A及IgG水平均有明显升高(P<0.01)。观察组中性粒细胞减少人数占比为25.71%,明显低于对照组的48.57%,差异有统计学意义(P<0.05)。结论:紫杉醇+替吉奥与奥沙利铂+替吉奥可获得相似的近期疗效及生存时间,但奥沙利铂+替吉奥更能改善GC患者的免疫功能,提高患者的耐受性,值得临床推广应用。
Objective:To compare the effect of the combination of paclitaxel and oxaliplatin in the adjuvant chemotherapy of gastric cancer(GC).Methods:73 patients with advanced GC diagnosed and treated in our hospital from October 2016 to October 2018 were selected as the main subjects.All of them were diagnosed by operation and pathology,and according to the simple random digital table method,divided into the observation group(n=36,chemotherapy of Oxaliposide and Tigiao)and the control group(n=37,chemotherapy of Tigiopaclitaxel and Tigiao).The recent curative effect and the change of the immune function index of the two groups were observed.The overall survival time(OS)of progression-free survival(PFS)was recorded as of October 31,2019,and also the recurrence rate of the two groups and the occurrence of the adverse reactions were recorded.Results:There was no significant difference between the two groups of disease control rate,the postoperative recurrence rate,the PFS and the OS(Pall>0.05).The levels of Ig A,IgG and IgM after chemotherapy in the two groups were significantly higher than those before chemotherapy(Pall<0.05).Compared with the control group,the levels of Ig A and IgG in the observation group were significantly higher than those in the control group(Pall<0.01).The proportion of neutrophils in the observation group was 25.71%,which was significantly lower than that in the control group(48.57%,P<0.05).Conclusion:The paclitaxel+tigecycline and oxaliplatin+teggio therapies can achieve similar near-term efficacy and survival time.But the oxaliplatin+teggio therapy can improve the immune function of the GC patients and improve the tolerance of the patients,and is worthy of clinical promotion and application.
作者
汪春梅
周国志
WANG Chunmei;ZHOU Guozhi(Yifu Hospital,Nanjing Medical University,Jiangsu Nanjing 210000,China)
出处
《河北医学》
CAS
2020年第7期1160-1164,共5页
Hebei Medicine
基金
江苏省自然科学基金项目,(编号:BK20170530)。
关键词
胃癌
紫杉醇
奥沙利铂
化疗
替吉奥
疗效
Gastric cancer
Paclitaxel
Oxaliplatin
Chemotherapy
Tegio
Curative effect
